Target detail
ABL2
ABL proto-oncogene 2, non-receptor tyrosine kinase
Data: Live structured evidence (Supabase)
Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).
Display name: ABL proto-oncogene 2, non-receptor tyrosine kinase
Aliases: ABL2, ABL proto-oncogene 2, non-receptor tyrosine kinase
Type / organism: protein_coding · Homo sapiens
Source: opentargets · ENSG00000143322
Index freshness: last_synced_at 2026-05-15T18:25:27.571+00:00 · updated 2026-05-15T18:25:28.019482+00:00
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.
Connectors represented in loaded rows for ABL2. Empty groups mean no matching rows — not a claim about biology or clinical use.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
- ChEMBLLive when indexed
Drug–target and related enrichment rows when operators run enrich:chembl (server/CLI only).
- CANTI signal builderLive when indexed
Deterministic repurposing-signal rows produced by the in-repo signal builder when operators run the build pipeline.
Rows from disease_target_evidence for this symbol.
glioblastoma
literature · opentargets
Drug records tied via drug_targets — mechanistic linkage only.
GSK-248233A
chembl220465
GSK-466314A
chembl218720
CHEMBL511337
chembl511337
CHEMBL275200
chembl275200
GSK-2186269A
chembl458415
CHEMBL478649
chembl478649
PELITINIB
chembl607707
GW819077X
chembl189415
GW683003X
chembl446024
GW830365A
chembl1909361
GSK-943949A
chembl1096634
PAZOPANIB
chembl477772
AST-487
chembl574738
GW577921A
chembl1794062
STAUROSPORINE
chembl388978
CHEMBL1765717
chembl1765717
GW282974X
chembl30432
GW683768X
chembl524057
CHEMBL516312
chembl516312
GSK-1220512A
chembl458865
GW853609X
chembl480371
GW284408X
chembl1794057
CHEMBL261440
chembl261440
CHEMBL526901
chembl526901
CHEMBL188048
chembl188048
CHEMBL1909411
chembl1909411
A-443654
chembl379300
SORAFENIB
chembl1336
CHEMBL397570
chembl397570
CHEMBL1233882
chembl1233882
GW659386A
chembl1909366
GSK-635416A
chembl230592
GW632580X
chembl261849
CHEMBL156263
chembl156263
GW820759X
chembl495902
CHEMBL1909347
chembl1909347
VANDETANIB
chembl24828
GW300657X
chembl272165
SP-600125
chembl1725279
GW784684X
chembl475761
GW574782A
chembl1909389
GW832467X
chembl188247
GW632046X
chembl192417
CHEMBL13868
chembl13868
CRIZOTINIB
chembl601719
CHEMBL1964275
chembl1964275
GSK-949675A
chembl1909350
CHEMBL450519
chembl450519
CHEMBL1822054
chembl1822054
GSK-182497A
chembl517123
GSK-269962B
chembl1909363
ENZASTAURIN
chembl300138
AFATINIB
chembl1173655
GW830900A
chembl1909362
GW703087X
chembl205798
CHEMBL2062289
chembl2062289
GW445012X
chembl218859
GW809897X
chembl189353
GW575533A
chembl1794060
CHEMBL1761145
chembl1761145
CHEMBL275798
chembl275798
FEDRATINIB
chembl1287853
GSK-579289A
chembl1794070
GW607049C
chembl1909365
GW607117X
chembl270164
GW445014X
chembl263796
GW434756X
chembl485745
GSK-571989A
chembl1794069
CHEMBL1644616
chembl1644616
GW441756X
chembl1516890
GSK-1007102B
chembl1909349
GW694234A
chembl1909370
GW405841X
chembl1794052
GW416469X
chembl272414
CHEMBL1081678
chembl1081678
CHEMBL215803
chembl215803
PHA-665752
chembl450786
CHEMBL399410
chembl399410
PI-103
chembl573339
GW615311X
chembl212250
GW275944X
chembl271843
GW301784X
chembl410072
GW567808A
chembl1909387
CHEMBL257167
chembl257167
CHEMBL95502
chembl95502
GW559768X
chembl237347
GSK-466317A
chembl427058
GW435821X
chembl218088
GW572738X
chembl234838
LESTAURTINIB
chembl603469
SB-202190
chembl278041
CHEMBL1909343
chembl1909343
CHEMBL1163518
chembl1163518
GSK-994854A
chembl513897
CHEMBL1785002
chembl1785002
CHEMBL1164180
chembl1164180
GW561436X
chembl1885746
PYRAZOLOPYRIMIDINE 2
chembl66292
BOSUTINIB
chembl288441
GW827106X
chembl188257
PICTILISIB
chembl521851
CHEMBL1956070
chembl1956070
CHEMBL1909413
chembl1909413
GW782912X
chembl517507
GW654652C
chembl1909358
BX-795
chembl577784
NILOTINIB
chembl255863
GW305178X
chembl409892
MOTESANIB
chembl572881
GW589933X
chembl1794055
GW874091X
chembl486124
CHEMBL102936
chembl102936
GW673715X
chembl243907
GSK-614526A
chembl1909375
GW709042A
chembl1909374
GW829115X
chembl188794
GW574783B
chembl529066
CHEMBL1164265
chembl1164265
CHEMBL1908395
chembl1908395
CHEMBL1241578
chembl1241578
GW827102X
chembl362155
GW780056X
chembl1882194
GW549390X
chembl318728
CHEMBL156987
chembl156987
GW811761X
chembl183993
GW807930X
chembl207247
CHEMBL1164181
chembl1164181
GSK-2163632A
chembl463931
GW278681X
chembl1794058
GW459057A
chembl1909354
HESPERADIN
chembl514409
TG100-115
chembl230011
GW856804X
chembl241517
CHEMBL525191
chembl525191
CHEMBL86755
chembl86755
CHEMBL408019
chembl408019
GSK-2213727A
chembl511765
GSK-1000163A
chembl1096290
RUBOXISTAURIN
chembl91829
CHEMBL3215582
chembl3215582
GSK-938890A
chembl1096626
GW827099X
chembl365297
CHEMBL1909412
chembl1909412
GSK-461364
chembl1908394
GW781673X
chembl513330
GSK-326090A
chembl1794068
CHEMBL347580
chembl347580
GW772405X
chembl207410
LINIFANIB
chembl223360
CHEMBL417804
chembl417804
CHEMBL1909345
chembl1909345
GSK-1023156A
chembl518953
CHEMBL400754
chembl400754
GW572401X
chembl275473
CHEMBL1171523
chembl1171523
GW693917A
chembl1909369
CHEMBL1760997
chembl1760997
SU-014813
chembl1721885
CHEMBL188268
chembl188268
GW711782X
chembl208437
CHEMBL604483
chembl604483
GSK-554170A
chembl1794065
GW279320X
chembl1909397
GSK-1030059A
chembl471789
GW801372X
chembl359999
GSK-969786A
chembl514938
GW814408X
chembl206010
GW782907X
chembl477978
CHEMBL1233881
chembl1233881
GW794607X
chembl67241
BRIVANIB
chembl377300
KW-2449
chembl1908397
CHEMBL249097
chembl249097
CHEMBL1760998
chembl1760998
GSK-1030061A
chembl518968
CHEMBL1908396
chembl1908396
GW580509X
chembl179311
GW813360X
chembl204934
GW806742X
chembl188381
GW784752X
chembl306865
CHEMBL1888586
chembl1888586
CHEMBL189231
chembl189231
SELUMETINIB
chembl1614701
GSK-200398A
chembl1909408
CHEMBL157258
chembl157258
GW795486X
chembl396107
CHEMBL515466
chembl515466
GW282449A
chembl1909380
GSK-238583A
chembl1909409
CHEMBL185710
chembl185710
CHEMBL101804
chembl101804
GW300660X
chembl272028
GW770249A
chembl588025
GW837331X
chembl520037
GW568377A
chembl1909388
BI-2536
chembl513909
CHEMBL1234815
chembl1234815
AT-7519
chembl445813
GSK-978744A
chembl1794067
GW683134A
chembl1909368
disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Mirror rows whose text fields mention this symbol — registry context only.
No matching live evidence found
Populate clinical_trials via the registry enrichment flow; this panel matches the symbol token in titles, conditions, or interventions.
Repurposing signal rows for drugs linked to this target via drug_targets.
Repurposing research signal · AST-487 · v0.1
Deterministic research signal for AST-487. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · BMS-387032 · v0.1
Deterministic research signal for BMS-387032. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · BOSUTINIB · v0.1
Deterministic research signal for BOSUTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · CANERTINIB · v0.1
Deterministic research signal for CANERTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · ALVOCIDIB · v0.1
Deterministic research signal for ALVOCIDIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubStructured rows with negative evidence_direction on disease–drug or signal tables.
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
No ClinicalTrials.gov mirror rows mention this symbol in titles, conditions, or interventions (within the loaded window).
- chembl: 439
- canti_signal_builder: 5
- opentargets: 1
Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.
Disease contexts
0
Linked drugs
0
Linked in dataset
0
Research signals
0
Doctor-discussion candidate and related tags are descriptive only.
Signals list: Live structured evidence (Supabase)
Repurposing research signal · ALVOCIDIB · v0.1
Deterministic research signal for ALVOCIDIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · CANERTINIB · v0.1
Deterministic research signal for CANERTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · BOSUTINIB · v0.1
Deterministic research signal for BOSUTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · AST-487 · v0.1
Deterministic research signal for AST-487. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · BMS-387032 · v0.1
Deterministic research signal for BMS-387032. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hub